TY - JOUR
T1 - Association between Heat Shock Protein-60 and Development of Atrial Fibrillation
T2 - Results from the Multi-Ethnic Study of Atherosclerosis (MESA)
AU - Maan, Abhishek
AU - Jorgensen, Neal W.
AU - Mansour, Moussa
AU - Dudley, Samuel
AU - Jenny, Nancy S.
AU - Defilippi, Christopher
AU - Szklo, Moyses
AU - Alonso, Alvaro
AU - Refaat, Marwan M.
AU - Ruskin, Jeremy
AU - Heckbert, Susan R.
AU - Heist, E. Kevin
N1 - Publisher Copyright:
© 2016 Wiley Periodicals, Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background: During atrial fibrillation (AF), a high rate of myocyte activation causes cellular stress and initiates the process of atrial remodeling, which further promotes persistence of AF. Although heat shock proteins (HSPs) have been shown to prevent atrial remodeling and suppress the occurrence of AF in cellular and animal experimental models, increased levels of HSP-60 have been observed in patients with postoperative AF, likely reflecting a response to cellular stress. To better understand the role of HSP-60 in relation to AF, we examined the association of HSP-60 levels in relation to the future development of AF in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: MESA is a cohort study that recruited 6,814 participants aged 45–84 years and free of known cardiovascular disease at baseline (2000–2002) from six field centers. We investigated 983 participants, selected at random from the total cohort, who had HSP-60 measured and were free of AF at baseline. We tested the association of HSP-60 levels with the incidence of AF using multivariate Cox models after adjustment for demographics, clinical characteristics, and biomarkers. Results: During an average of 10.6 years of follow-up, 77 participants developed AF. We did not observe a significant association between the log-transformed HSP-60 levels and development of AF on either unadjusted or multivariate analysis (adjusted hazard ratio: 1.02 per unit difference on natural log scale, 95% confidence interval: 0.77–1.34 ln (ng/mL). Conclusion: Contrary to the findings from the preclinical studies, which demonstrated an important role of HSP-60 in the pathogenesis of AF, we did not observe a significant association between HSP-60 and occurrence of AF.
AB - Background: During atrial fibrillation (AF), a high rate of myocyte activation causes cellular stress and initiates the process of atrial remodeling, which further promotes persistence of AF. Although heat shock proteins (HSPs) have been shown to prevent atrial remodeling and suppress the occurrence of AF in cellular and animal experimental models, increased levels of HSP-60 have been observed in patients with postoperative AF, likely reflecting a response to cellular stress. To better understand the role of HSP-60 in relation to AF, we examined the association of HSP-60 levels in relation to the future development of AF in the Multi-Ethnic Study of Atherosclerosis (MESA). Methods: MESA is a cohort study that recruited 6,814 participants aged 45–84 years and free of known cardiovascular disease at baseline (2000–2002) from six field centers. We investigated 983 participants, selected at random from the total cohort, who had HSP-60 measured and were free of AF at baseline. We tested the association of HSP-60 levels with the incidence of AF using multivariate Cox models after adjustment for demographics, clinical characteristics, and biomarkers. Results: During an average of 10.6 years of follow-up, 77 participants developed AF. We did not observe a significant association between the log-transformed HSP-60 levels and development of AF on either unadjusted or multivariate analysis (adjusted hazard ratio: 1.02 per unit difference on natural log scale, 95% confidence interval: 0.77–1.34 ln (ng/mL). Conclusion: Contrary to the findings from the preclinical studies, which demonstrated an important role of HSP-60 in the pathogenesis of AF, we did not observe a significant association between HSP-60 and occurrence of AF.
KW - atrial fibrillation
KW - atrial stress response
KW - heat shock protein
UR - http://www.scopus.com/inward/record.url?scp=85006325089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006325089&partnerID=8YFLogxK
U2 - 10.1111/pace.12969
DO - 10.1111/pace.12969
M3 - Article
C2 - 27807875
AN - SCOPUS:85006325089
SN - 0147-8389
VL - 39
SP - 1373
EP - 1378
JO - PACE - Pacing and Clinical Electrophysiology
JF - PACE - Pacing and Clinical Electrophysiology
IS - 12
ER -